Asia Pacific Insulin Market For Type 1 And Type 2 Diabetes Market
Market Size in USD Billion
CAGR :
% 
USD
3.88 Billion
USD
5.75 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 3.88 Billion |
 Market Size (Forecast Year) |
USD 5.75 Billion |
 CAGR |
% |
| Major Markets Players |
|
Asia Pacific Insulin Market for Type 1 And Type 2 Diabetes Segmentation, Type (Type 2 Diabetes and Type 1 Diabetes), Product Type (Long Acting Insulin, Rapid-Acting Insulin, Short Acting Insulin, and Others), Absorption Site (Basal, Bolus, and Others), Age Group (Adult Patients, Geriatric Patients, and Pediatric Patients), Source (Analog Insulin, Human Insulin, and Others), Delivery Method (Insulin Pens, Vial & Syringe, Insulin Pumps, Inhalable Insulin, and Implantable Insulin Delivery Systems), Gender (Male and Female), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Diabetes Clinics & Specialty Pharmacies)- Industry Trends and Forecast to 2032
Insulin Market for Type 1 And Type 2 Diabetes Market Size
- The Asia-Pacific insulin market for type 1 and type 2 diabetes market was valued at USD 3.88 billion in 2024 and is expected to reach USD 5.75 billion by 2032
- During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 5.1%, primarily driven by the anticipated launch of therapies
- This growth is driven by factors such as the growing prevalence of diabetes, particularly Type 1 and Type 2, drives the demand for insulin. Additionally, advancements in insulin delivery systems and the increasing adoption of personalized diabetes care
Insulin Market for Type 1 And Type 2 Diabetes Market Analysis
- Type 1 diabetes is an autoimmune condition where the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas, leading to an insulin deficiency. Type 2 diabetes occurs when the body becomes resistant to insulin or doesn't produce enough. Insulin therapy is used to regulate blood glucose levels in both conditions, improving glycemic control and preventing complications like cardiovascular diseases, kidney failure, and nerve damage
- Type 1 diabetes (T1D) is typically diagnosed in childhood or adolescence and requires lifelong insulin therapy, as the pancreas produces little to no insulin. It is an autoimmune disorder where the immune system mistakenly attacks insulin-producing beta cells. Type 2 Diabetes (T2D) is more common and primarily occurs in adults, although it is increasingly seen in children due to rising obesity rates. T2D is characterized by insulin resistance, where the body does not use insulin effectively. Over time, the pancreas cannot produce enough insulin to maintain normal blood glucose levels. Both types of diabetes require regular monitoring and insulin therapy to manage blood sugar levels effectively. Insulin treatment helps in preventing long-term complications like retinopathy, neuropathy, and cardiovascular diseases, improving the overall quality of life for patients
- The China stands out as one of the dominant region for Insulin Market for Type 1 And Type 2 Diabetes, driven by its advanced healthcare infrastructure and high adoption of innovative insulin delivery technologies
- For instance, China continues to lead in the use of insulin pumps and continuous glucose monitoring systems, enabling better diabetes management
- With a growing focus on diabetes treatment and patient-centric solutions, the region drives significant advancements in insulin therapies, contributing greatly to market growth
Report Scope and Insulin Market for Type 1 and Type 2 Diabetes Segmentation
|
Attributes |
Insulin Market for Type 1 and Type 2 Diabetes Market Insights |
|
Segments Covered |
|
|
Countries Covered |
Asia-Pacific
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Insulin Market for Type 1 And Type 2 Diabetes Market Trends
“Increased Adoption of Smart Insulin Delivery Systems”
- One prominent trend in the Insulin Market for Type 1 and Type 2 Diabetes is the growing adoption of smart insulin delivery systems.
- These advanced devices enhance diabetes management by offering real-time monitoring and insulin dose adjustments based on glucose levels, improving precision and overall treatment outcomes
- For instance, insulin pumps integrated with continuous glucose monitoring (CGM) systems allow for automated insulin delivery, adjusting doses based on real-time data, which helps maintain optimal glucose control with minimal manual intervention
- Digital platforms also facilitate seamless data tracking, enabling patients and healthcare providers to monitor trends, improve treatment plans, and prevent complications
- This trend is transforming diabetes care, promoting better patient compliance and outcomes, and driving the demand for advanced insulin delivery technologies in the market
Insulin Market for Type 1 And Type 2 Diabetes Market Dynamics
Driver
“Rising Prevalence of Diabetes”
- The increasing number of individuals diagnosed with diabetes creates a substantial demand for effective insulin therapies, which in turn drives growth in the insulin market. Factors such as sedentary lifestyles, unhealthy diets, and an aging population contribute to this trend, resulting in a larger patient base requiring diabetes management solutions
- The heightened need for insulin products spurs innovation and competition among pharmaceutical companies, leading to the development of new formulations and delivery methods. This dynamic environment supports existing therapies and encourages the introduction of affordable biosimilars and improved technologies, further expanding market opportunities
For instance,
- In 2024, as per WHO, the number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022. This rise was more rapid in low- and middle-income countries than in high-income countries. Diabetes caused over 2 million deaths in 2021, with significant complications like kidney failure and heart disease
- In March 2024, as per NCBI, diabetes prevalence has significantly increased, with 537 million adults affected in 2021, representing 10.5% of the population. By 2030, this number is projected to rise to 643 million (11.3%). Diabetes-related healthcare costs were $966 billion in 2021, expected to exceed $1054 billion by 2045
- The rising prevalence of diabetes is fueling the need for innovative and convenient treatments, which can significantly improve patient quality of life and adherence to therapy. While challenges related to bioavailability and production costs remain, the market potential is vast, offering a promising solution for both Type 1 and Type 2 diabetes management
Opportunity
“Advancements in Insulin Formulation and Delivery Technologies”
- Advancements in insulin drug formulation, including nanoparticle carriers, mucoadhesive agents, and pH-sensitive coatings, have significantly improved the bioavailability of oral insulin, making it a viable alternative to traditional injections. Innovations such as insulin analogs and smart drug delivery systems enhance absorption and enable real-time glucose monitoring. These breakthroughs address patient adherence, particularly in emerging markets with increasing diabetes prevalence, creating significant growth opportunities for the oral insulin market
For instance,
- A July 2020 article by NCBI highlighted that the urgent need for innovative treatments to address the growing diabetes burden. Key needs include improving patient adherence to treatment regimens, reducing healthcare costs, and providing effective, non-invasive solutions for diabetes management. Advancements like oral insulin and smart drug delivery systems present promising opportunities to meet these challenges and improve patient outcomes
- In August 2024, MDPI reported that advancements in drug delivery systems, such as nanoparticles and liposomes, to improve oral insulin bioavailability. These innovations offer a significant opportunity to enhance diabetes management by providing non-invasive, effective treatments. As global diabetes rates rise, such advancements meet the increasing demand for patient-centric solutions. As diabetes prevalence grows globally, these advancements in drug delivery systems cater to the need for more accessible, patient-focused treatments
- The ongoing advancements in drug formulation and technology are transforming the oral insulin landscape, providing significant opportunities for better management of diabetes. Innovations in bioavailability enhancement, novel drug delivery systems, and the integration of digital health tools pave the way for oral insulin to become a reliable, non-invasive alternative to injectable therapies. As the global diabetes epidemic continues to rise, these technological innovations not only boost patient adherence but also enable more efficient, tailored diabetes management, ultimately improving the quality of life
Restraint/Challenge
“Adverse Effects of High Dosage Of Insulin”
- High dosages of insulin can result in considerable adverse effects such as hypoglycemia, weight gain, and potential cardiovascular issues, which may discourage both patients and healthcare providers from embracing insulin therapies
- As a result, concerns over these complications can lead to greater caution in prescribing practices, ultimately hindering the expansion of the insulin market for Type 1 and Type 2 diabetes, as patients increasingly turn to alternative treatments or management strategies
For instance,
- In July 2023, NCBI stated that Hypoglycemia is the most common adverse effect of insulin therapy. The other adverse effects of insulin therapy include weight gain and rarely electrolyte disturbances such as hypokalemia, especially when used along with other drugs causing hypokalemia. Moreover, pain at the injection site and lipodystrophy at the injection site are the most common adverse effects of daily subcutaneous injections
- Moreover, the fear of adverse reactions from high dosages can result in increased healthcare costs due to hospitalization or the need for additional medications to manage side effects. This financial burden can limit access to insulin therapies, particularly in developing regions where healthcare resources are constrained, further contributing to a restrained global insulin market. Increased awareness and education about these risks are essential, but they also underline the challenges the market faces in encouraging widespread adherence to insulin regimens
Asia-Pacific Insulin Market for Type 1 And Type 2 Diabetes Market Scope
The market is segmented on the basis type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.
|
Segmentation |
Sub-Segmentation |
|
By Type |
|
|
By Product Type |
|
|
By Absorption Site |
|
|
By Age Group
|
|
|
By Source |
|
|
By Delivery Method |
|
|
By Gender
|
|
|
By Distribution Channel
|
|
Insulin Market for Type 1 and Type 2 Diabetes Market Regional Analysis
“China is the Dominant Country in the Insulin Market for Type 1 and Type 2 Diabetes”
- China dominates the Insulin Market for Type 1 and Type 2 Diabetes in the Asia Pacific region, driven by its large diabetic population, increasing healthcare access, and government initiatives to improve diabetes care
- China holds a significant share due to the rising prevalence of diabetes, particularly Type 2, driven by urbanization, lifestyle changes, and aging population trends. The growing awareness of diabetes management and treatment options further contributes to the demand for insulin
- The availability of well-established healthcare policies and robust reimbursement structures, along with substantial investments in research & development by top insulin manufacturers, further strengthens the market
- Additionally, the growing focus on personalized diabetes care, along with an increase in the adoption of insulin pumps and continuous glucose monitoring (CGM) systems, is fueling market expansion across the region
“China is Projected to Register the Highest Growth Rate”
- The China region is expected to witness the highest growth rate in the Insulin Market for Type 1 and Type 2 Diabetes, driven by rapid improvements in healthcare infrastructure, increasing awareness about diabetes management, and rising adoption of advanced insulin therapies
- India is emerging as key markets due to the growing aging population, which is more susceptible to diabetes-related complications
- China, with its advanced healthcare systems and increasing number of diabetes specialists, remains a crucial market for insulin therapies. The country continues to lead in the adoption of innovative insulin delivery devices, such as insulin pumps and continuous glucose monitoring (CGM) systems
- China, with its large diabetic populations and rising rates of diabetes-related health complications, are witnessing increased government and private sector investments in modern diabetes care solutions. The expanding presence of insulin manufacturers and improving access to advanced diabetes treatment options further contribute to market growth
Insulin Market for Type 1 and Type 2 Diabetes Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
The Major Market Leaders Operating in the Market Are:
- Novo Nordisk A/S (Denmark)
- Eli Lilly and Company (U.S.)
- Sanofi (France)
- Biocon (India)
- Lupin (India)
- Shanghai Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (China)
- Diasome Pharmaceuticals, Inc. (U.S.)
- SciGen Pte. Ltd. (Singapore)
- Wockhardt (India)
- MJ Biopharma Pvt. Ltd. (India)
- Oramed Pharmaceuticals (U.S.)
- Adocia (France)
- Nektar Therapeutics (U.S.)
Latest Developments in Asia-Pacific Insulin Market for Type 1 and Type 2 Diabetes
- In September 2024, Novo Nordisk has announced a new partnership to establish human insulin production in South Africa, strengthening its commitment to diabetes care in Africa. Currently reaching 500,000 people in Sub-Saharan Africa, this initiative aims to expand insulin access, with a goal of supplying 4.1 million people with type 1 and type 2 diabetes across the continent by 2026
- In August, Eli Lilly announced positive results from the SURMOUNT-1 study, showing that weekly tirzepatide (Zepbound/Mounjaro) reduced the risk of type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. The 15 mg dose led to a 22.9% average weight loss over 176 weeks, demonstrating sustained efficacy
- In December 2022, Sanofi expanded its collaboration with Innate Pharma, focusing on natural killer (NK) cell engagers in oncology. Sanofi licensed the B7H3-targeting NK cell engager program from Innate's ANKET platform, with the option to add two more targets. This partnership aims to develop new cancer therapies, including treatments for solid tumors, enhancing Sanofi's immuno-oncology pipeline. The collaboration is expected to provide innovative cancer treatment options with a strong safety profile, benefiting patients by offering potential therapies for multiple cancer types. Sanofi will handle further development, manufacturing, and commercialization responsibilities
- In December 2024, Lupin Acquired Huminsulin from Lilly to Enhance Diabetes Portfolio. It was performed in the aim to expand diabetes portfolio and provide high-quality, affordable health care to our patients
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 COMPETITIVE INTELLIGENCE
4.4 ASIA-PACIFIC AND REGIONAL PREVALENCE:
4.5 INDUSTRY INSIGHTS
4.6 KEY MARKETING STRATEGIES FOR THE ASIA-PACIFIC INSULIN MARKET TYPE 1 & TYPE 2 DIABETES
4.7 MARKETED DRUG ANALYSIS
5 PIPELINE ANALYSIS
6 REGULATORY FRAMEWORK
6.1 REGULATORY FRAMEWORK FOR THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.1.1 REGULATORY APPROVAL PROCESS
6.1.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.1.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.1.4 LICENSING AND REGISTRATION
6.1.5 POST-MARKETING SURVEILLANCE
6.1.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.2 REGULATORY FRAMEWORK FOR THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.2.1 REGULATORY APPROVAL PROCESS
6.2.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.2.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.2.4 LICENSING AND REGISTRATION
6.2.5 POST-MARKETING SURVEILLANCE
6.2.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.3 REGULATORY FRAMEWORK FOR THE SOUTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.3.1 REGULATORY APPROVAL PROCESS
6.3.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.3.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.3.4 LICENSING AND REGISTRATION
6.3.5 POST-MARKETING SURVEILLANCE
6.3.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.4 REGULATORY FRAMEWORK FOR THE EUROPE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.4.1 REGULATORY APPROVAL PROCESS
6.4.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.4.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.4.4 LICENSING AND REGISTRATION
6.4.5 POST-MARKETING SURVEILLANCE
6.4.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.5 REGULATORY FRAMEWORK FOR THE MIDDLE EAST & AFRICA (MEA) INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.5.1 REGULATORY APPROVAL PROCESS
6.5.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.5.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.5.4 LICENSING AND REGISTRATION
6.5.5 POST-MARKETING SURVEILLANCE
6.5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF DIABETES
7.1.2 GROWING ADOPTION OF INSULIN THERAPIES FOR TYPE 1 AND TYPE 2 DIABETES
7.1.3 INTEGRATION OF AUTOMATED INSULIN DELIVERY (AID)
7.1.4 INCREASING TECHNOLOGICAL INNOVATIONS FOR INSULIN
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS OF HIGH DOSAGE OF INSULIN
7.2.2 HIGH PRODUCTION AND DEVELOPMENT COSTS ASSOCIATED WITH INSULIN
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN INSULIN FORMULATION AND DELIVERY TECHNOLOGIES
7.3.2 REVOLUTIONIZING DIABETES MANAGEMENT WITH NEEDLE-FREE INSULIN
7.3.3 INCREASING PHARMACEUTICAL INVESTMENTS AND STRATEGIC COLLABORATIONS
7.4 CHALLENGES
7.4.1 INSULIN ACCESSIBILITY CHALLENGES IN RURAL AND UNDERSERVED REGIONS
7.4.2 LIMITED SHELF LIFE ASSOCIATED WITH ORAL INSULIN
8 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE
8.1 OVERVIEW
8.2 TYPE 2 DIABETES
8.3 TYPE 1 DIABETES
9 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE
9.1 OVERVIEW
9.2 ANALOG INSULIN
9.3 HUMAN INSULIN
9.4 OTHERS
10 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 LONG ACTING INSULIN
10.3 RAPID-ACTING INSULIN
10.4 SHORT ACTING INSULIN
10.5 OTHERS
11 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 INSULIN PENS
12.3 VIAL & SYRINGE
12.4 INSULIN PUMPS
12.5 INHALABLE INSULIN
12.6 IMPLANTABLE INSULIN DELIVERY SYSTEMS
13 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT PATIENTS
13.3 GERIATRIC PATIENTS
13.4 PEDIATRIC PATIENTS
14 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE
14.1 OVERVIEW
14.2 BASAL
14.3 BOLUS
14.4 OTHERS
15 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES
15.5 DIABETES CLINICS & SPECIALTY PHARMACIES
16 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 INDIA
16.1.3 JAPAN
16.1.4 SOUTH KOREA
16.1.5 AUSTRALIA
16.1.6 INDONESIA
16.1.7 THAILAND
16.1.8 MALAYSIA
16.1.9 VIETNAM
16.1.10 PHILIPPINES
16.1.11 TAIWAN
16.1.12 SINGAPORE
16.1.13 REST OF ASIA-PACIFIC
17 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 NOVO NORDISK A/S
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 SWOT ANALYSIS
19.1.5 PIPELINE PORTFOLIO
19.1.6 RECENT DEVELOPMENT/ NEWS
19.2 LILLY
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 SWOT ANALYSIS
19.2.5 PRODUCT PORTFOLIO
19.2.6 RECENT DEVELOPMENT
19.3 SANOFI
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENT
19.4 BIOCON
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 SWOT ANALYSIS
19.4.6 PIPELINE PRODUCT PORTFOLIO
19.4.7 RECENT DEVELOPMENT
19.5 LUPIN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 SWOT ANALYSIS
19.5.5 PRODUCT PORTFOLIO
19.5.6 RECENT DEVELOPMENT
19.6 ADOCIA
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 SWOT ANALYSIS
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENT
19.7 DIASOME PHARMACEUTICALS, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 SWOT ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 MJ BIOPHARM PVT LTD.
19.8.1 COMPANY SNAPSHOT
19.8.2 SWOT ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 NEKTAR
19.9.1 COMPANY SNAPSHOT
19.9.2 SWOT ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT NEWS
19.1 ORAMED
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 SWOT ANALYSIS
19.10.4 PIPELINE PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPMENT
19.11 SCIGEN PTE. LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 SWOT ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 SHANGHAI FOSUN PHARMACEUTICAL（GROUP）CO., LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENT
19.13 WOCKHARDT
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
20 QUESTIONNAIRE
List of Table
TABLE 1 THE TOP 10 COUNTRIES BY THE NUMBER OF ADULTS WITH DIABETES IN 2021
TABLE 2 DISTRIBUTION OF EXPENDITURE ACROSS REGIONS:
TABLE 3 NUMBER OF ADULTS WITH DIABETES IS EXPECTED TO INCREASE SIGNIFICANTLY IN SEVERAL COUNTRIES:
TABLE 4 REGIONAL DIABETES STATISTICS: PREVALENCE, TREATMENT, AND OUTCOMES
TABLE 5 ASIA-PACIFIC CLINICAL TRIAL MARKET FOR ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 7 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 8 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC TYPE 2 DIABETES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC TYPE 1 DIABETES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC ANALOG INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC HUMAN INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC LONG ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC RAPID-ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC SHORT ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC MALE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC FEMALE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC INSULIN PENS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC VIAL & SYRINGE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC INSULIN PUMPS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC INHALABLE INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC IMPLANTABLE INSULIN DELIVERY SYSTEMS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC ADULT PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC GERIATRIC PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC PEDIATRIC PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC BASAL IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC BOLUS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC RETAIL PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC HOSPITAL PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC ONLINE PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC DIABETES CLINICS & SPECIALTY PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 51 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 54 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 55 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 56 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 57 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 58 CHINA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 59 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 62 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 63 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 64 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 65 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 66 INDIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 67 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 70 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 71 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 72 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 73 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 74 JAPAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 75 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 78 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 79 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 80 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 81 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 82 SOUTH KOREA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 83 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 86 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 87 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 88 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 89 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 90 AUSTRALIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 91 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 94 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 95 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 96 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 97 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 98 INDONESIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 99 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 102 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 103 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 104 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 105 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 106 THAILAND INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 107 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 110 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 111 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 112 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 113 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 114 MALAYSIA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 115 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 118 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 119 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 120 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 121 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 122 VIETNAM INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 123 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 126 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 127 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 128 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 129 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 130 PHILIPPINES INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 131 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 134 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 135 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 136 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 137 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 138 TAIWAN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 139 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 142 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 143 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 144 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 145 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 146 SINGAPORE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 147 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 150 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 151 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 152 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 153 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 154 REST OF ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SEGMENTATION
FIGURE 2 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SEGMENTATION
FIGURE 10 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE
FIGURE 11 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING PREVALENCE OF DIABETES IS EXPECTED TO DRIVE THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 TYPE 2 DIABETES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 15 TOP 10 COUNTRIES BY THE NUMBER OF ADULTS WITH DIABETES IN 2021
FIGURE 16 ASIA-PACIFIC HEALTHCARE EXPENDITURE FOR DIABETES
FIGURE 17 NUMBER OF PEOPLE WITH DIABETES IN 2045 (MILLIONS)
FIGURE 18 DROC ANALYSIS
FIGURE 19 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, 2024
FIGURE 20 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 21 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, CAGR (2025-2032)
FIGURE 22 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, 2024
FIGURE 24 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, 2025 TO 2032 (USD THOUSAND)
FIGURE 25 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, CAGR (2025-2032)
FIGURE 26 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, 2024
FIGURE 28 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 29 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, CAGR (2025-2032)
FIGURE 30 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, 2024
FIGURE 32 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 33 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, CAGR (2025-2032)
FIGURE 34 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, 2024
FIGURE 36 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, 2025 TO 2032 (USD THOUSAND)
FIGURE 37 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, CAGR (2025-2032)
FIGURE 38 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, 2024
FIGURE 40 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, 2025 TO 2032 (USD THOUSAND)
FIGURE 41 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, CAGR (2025-2032)
FIGURE 42 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, 2024
FIGURE 44 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, 2025 TO 2032 (USD THOUSAND)
FIGURE 45 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, CAGR (2025-2032)
FIGURE 46 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, 2024
FIGURE 48 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 49 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 50 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SNAPSHOT (2024)
FIGURE 52 ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY SHARE 2024 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
